StockNews.AI
SNN
StockNews.AI
71 days

New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility

1. SNN's new medial stabilized inserts enhance LEGION Total Knee System's efficiency. 2. Popularity of medial stabilized designs grew from 4% to 32% in five years. 3. US registry shows one in three total knees now use medial stabilized designs. 4. SNN plans full commercial release of the new insert by 2025. 5. The design aims for higher patient satisfaction and better natural knee movement.

9m saved
Insight
Article

FAQ

Why Bullish?

SNN introduces an innovative product aligning with market trends, likely boosting demand.

How important is it?

The introduction of a new product in a growing market is crucial for SNN's future.

Why Long Term?

Full commercial release in 2025 and growing demand suggest sustained market growth.

Related Companies

JNJMDTZBH
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1 With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone-conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient.2  The medial stabilized design aims to maintain stability with a larger anterior medial lip and medial pivot kinematics similar to the natural knee. “We’re entering an exciting era in knee replacement, driven by the momentum of personalized medicine and an influx of innovative approaches,” said Dr. Steve McDonald, Chief of Orthopaedics and Chief of Surgery, at London Health Sciences Centre in London, Ontario. “With US registry data now showing that one in three total knees utilize a medial stabilized design, it’s clear that surgeons are increasingly turning to solutions that offer more natural kinematics and higher patient satisfaction. The LEGION Medial Stabilized TKS stands out in this space - offering a powerful combination of medial stabilized kinematics, advanced porous fixation, integration with technologies like the CORI◊ Surgical System, and a strong clinical legacy. It’s an ideal solution for surgeons looking to align with the principles of personalized care.” The LEGION TKS has demonstrated more than 20 years of clinical success,3 with the new medial stabilized insert adding a modern design to align with rapidly growing market trends. The LEGION Medial Stabilized TKS is the latest addition to the LEGION portfolio supporting both the LEGION CONCELOC◊ Cementless and LEGION Cemented Total Knee Systems. “LEGION Medial Stabilized TKS is the latest evolution of the trusted LEGION brand - a platform backed by over 20 years of performance and innovation,” said Craig Gaffin, President, Global Orthopaedics for Smith+Nephew. “As market demand for porous and kinematically advanced knee solutions continues to grow, we believe this addition will elevate the LEGION portfolio even further, enabling us to better meet the evolving needs of patients and surgeons alike.” The medial stabilized insert for LEGION TKS is available in the US on a limited basis, with a full commercial release later in 2025. The system will also be introduced in Canada in 2026. To hear more from Dr. MacDonald and Craig Gaffin, please visit here.  - ends - Enquiries Media David Snyder+1 978-749-1440Smith+Nephew  References American Joint Replacement Registry (AJRR) 2024 Annual Report.https://pmc.ncbi.nlm.nih.gov/articles/PMC12089135/#s4 Victor J, Ghijselings S, Tajdar F, et al. Total knee arthroplasty at 15-17 years: does implant design affect outcome? Int Orthop. 2014;38(2):235-241. About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Related News